HA1077 enhances the cytokeratin expression of mesenchymal stem cells.
The objective of the study is to investigate the effect of fasudil [1-(5-isoquinolinesulfonyl) homopiperazine] (HA1077, calcium antagonist vasodilator and an inhibitor of RhoA kinase) on expression of cytokeratin (CK), DNA multiplication, and synthesis of mesenchymal stem cells (MSC). After rats were killed, MSC were separated from rats and proliferated in culture medium. The cells were randomly divided into control group, HA1077 control group, induction group, and HA1077 group. The percentage of CK19+MSC, proliferating cell nuclear antigen (PCNA), and cell cycle were determined. The test was repeated for five times. SPSS 12 software was used to analyze all the data. A P value <.05 and P < .01 were considered to be significant. The flow cytometry result showed that 1) the isolated MSC were uniformly positive for CD44, SSEA-1, CD105 but were negative for CD34, CD14, and CD45. 2) In the HA1077 control group, the percentage of CK19+MSC was similar to that in control group, which was lower than that in the induction group. In the HA1077 group, the percentage of CK19+MSC was higher than in the induction group (P < .01), in HA1077 control group (P < .01), and in control group (P < .01). 3) PCNA-positive rate in HA1077 group was highest among the groups. PCNA-positive rate of induction group was higher than that of control group and HA1077 control group. The cell cycle analysis showed that the quantity of MSC in S phase of HA1077 group was also highest. The quantity of MSC in S phase of induction group was higher than that of control group and HA1077 control group. There was no difference between the HA1077 control group and control group. HA1077 can repair burn wounds in future by promoting MSC differentiating into epidermal cell through DNA multiplication and synthesis.
Xiaodong
Bai
B
Burn and Plastic Department, The General Hospital of Chinese Armed Police Forces, Beijing, China.
Xianhua
Liu
L
Xiaojie
Liu
L
D019307:1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine / Q000031:analogs & derivatives* / Q000494:pharmacology; D000818:Animals; D015703:Antigens, CD / Q000378:metabolism; D002453:Cell Cycle; D005434:Flow Cytometry; D007124:Immunoenzyme Techniques; D007633:Keratins / Q000378:metabolism*; D059630:Mesenchymal Stem Cells / Q000187:drug effects* / Q000378:metabolism*; D018809:Proliferating Cell Nuclear Antigen / Q000378:metabolism; D011897:Random Allocation; D051381:Rats; D017208:Rats, Wistar; D014945:Wound Healing / Q000502:physiology
D015703:Antigens, CD; D018809:Proliferating Cell Nuclear Antigen; D007633:Keratins; D019307:1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; C049347:fasudil